人类乳突病毒市场：规模、细分、份额、法规、报销、程序、到 2033 年的预测

人类乳突病毒（HPV）被称为世界上最常见的性传染感染（STI）。 人类乳突病毒 (HPV) 检测主要用于筛检子宫颈癌和/或识别子宫颈癌风险较高的女性。 HPV有150多种类型，包括高危险HPV和低危险HPV。 在这些类型中，HPV-16 和 HPV-18 最常与子宫颈癌的发生有关。

核酸扩增（NAAT）检测是HPV检测的主流，具有较高的特异性和敏感性，可适应高通量检测。 已经报导了其他几种 HPV DNA 检测方法，包括原位杂交测试、□联免疫吸附测定 (EIA) 或□联免疫吸附测定 (ELISA) 试剂盒以及下一代测序测定。 有利的政府政策、HPV 感染的高发生率以及子宫颈癌筛检意识计划的提高等因素预计将在预测期内推动整个 HPV 检测市场的发展。 尖圭湿疣通常是由非致癌性 HPV 病毒株（例如 HPV-6 和 HPV-11）引起的。

HPV检测包括人类乳突病毒（HPV）核酸扩增检测（NAAT）和其他人类乳突病毒（HPV）检测试剂盒。

本报告深入探讨了全球人类乳突病毒市场，包括竞争格局、SWOT 分析、到 2033 年的市场预测、COVID-19 的影响、区域和国家趋势等。Masu。

目录

目前市面上的人类乳突病毒及竞争状况

• 对主要产业趋势的见解
• 2015 年至 2033 年按细分市场划分的人类乳突病毒市场总收入及市场前景
• 有关数量、平均售价和市场价值的详细数据

全球、区域与国家见解

• 人类乳突病毒市场的SWOT分析
• 人类乳突病毒市场的竞争动态洞察与趋势
• 各国医疗保健系统概览
• 按国家/地区划分的报销政策
• 各国医疗科技的监管状况

Abstract

Human Papilloma Virus Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.

The model discusses in detail the impact of COVID-19 on Human Papilloma Virus Tests market for the year 2020 and beyond. Human papillomavirus (HPV) is known as the most common sexually transmitted infection (STI) in the world. Human Papillomavirus (HPV) Tests are primarily used to screen for cervical cancer and/or identify women who may be at increased risk of cervical cancer. There are over 150 types of HPV including both high-risk HPV and low-risk HPV. Out of these strains, types HPV-16 and HPV-18 are most commonly associated with development of cervical cancer.

The predominant devices used for HPV detection are Nucleic-acid amplification (NAAT) tests, owing to their high specificity and sensitivity as well as their ability to be adapted for high-throughput testing. Several other HPV DNA detection methods have also been described including in situ hybridization tests, Enzyme Immunoassay (EIA) or enzyme-linked immunosorbent assay (ELISA) kits, and next generation sequencing assays. Factors like favorable government policies, high occurrence rate of HPV infections, and growing cervical cancer screening awareness plans are expected to drive the overall HPV testing market during the forecast period. Genital warts are often caused by non-oncogenic strains of HPV, such as HPV-6 and HPV-11.

The HPV tests includes Human Papilloma Virus (HPV) Nucleic Acid Amplification Tests (NAATs) and Other Human Papilloma Virus (HPV) Test Kits.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are:

Currently marketed Human Papilloma Virus Tests and evolving competitive landscape:

• Insightful review of the key industry trends.
• Annualized total Human Papilloma Virus Tests market revenue by segment and market outlooks from 2015-2033.
• Market level data on units, average selling prices and market values.

Global, Regional and Country level market specific insights:

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Human Papilloma Virus market.
• Competitive dynamics insights and trends provided for Human Papilloma Virus market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Hologic Inc, Qiagen NV, F. Hoffmann-La Roche Ltd, Abbott Laboratories, Biocare Medical LLC, Enzo Biochem Inc, Danaher Corp, Thermo Fisher Scientific Inc and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

• CMO executives who must have deep understanding of the Human Papilloma Virus (HPV) Tests market place to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to:

• Understand the impact of COVID-19 on Human Papilloma Virus (HPV) Tests market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Human Papilloma Virus (HPV) Tests market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Human Papilloma Virus (HPV) Tests market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
• Track device sales in the global and country-specific Human Papilloma Virus (HPV) Tests market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.